Featured Research

from universities, journals, and other organizations

Targeted therapy proves effective against brain tumors in preclinical studies

Date:
December 21, 2012
Source:
Roswell Park Cancer Institute
Summary:
Researchers have published the first evidence that inhibiting focal adhesion kinase with CFAK-Y15 can control the growth of glioblastoma tumors.

Researchers from Roswell Park Cancer Institute (RPCI) have published findings from a preclinical study assessing the effectiveness of a small-molecule inhibitor, CFAK-Y15, in treating some brain cancers. The paper, published in Molecular Cancer Therapeutics, demonstrates for the first time that inhibiting the protein focal adhesion kinase (FAK) with CFAK-Y15 is an effective approach to controlling growth of glioblastoma tumors, especially in combination with the standard chemotherapy agent temozolomide (Temodar).

FAK is overexpressed, or produced in excessive amounts, in tumor cells, and has been shown to play a key role in survival of cancer cells. In this study, a team led by Vita M. Golubovskaya, PhD, an Associate Professor of Oncology in the Department of Surgical Oncology, found that animal models treated with CFAK-Y15 demonstrated significantly prolonged survival compared to the control group. CFAK-Y15 provides FAK kinase-specific inhibition by upstream targeting of autophosphorylation sites on the FAK protein. It belongs to a class of 'two for one' compounds that also inhibit the oncoprotein Src by inhibiting its autophosphorylation.

"We found that CFAK-Y15 significantly decreased the viability of the glioblastoma cells, and in many cases appeared to cause tumor shrinkage -- especially when CFAK-Y15 was given in combination with temozolomide," noted Dr. Golubovskaya, the paper's first author. "These compounds target FAK signaling, which is critical for cancer cell and cancer stem cell survival, especially in invasive and metastatic cancers."

"We're eager to see this research move to the clinical phase because of the great need for more effective treatments for glioblastoma," noted senior author William G. Cance, MD, FACS, Surgeon-in-Chief and Chair of the Department of Surgical Oncology. "The potential impact is great because glioblastomas are such an aggressive tumor, and because we know they produce FAK in especially high quantities."

The authors also included researchers from the University of California at San Diego and faculty from the Department of Pathology at RPCI. CFAK-Y15 is being developed by CureFAKtor Pharmaceuticals LLC. Drs. Cance and Golubovskaya, both of whom also serve on the management team of CureFAKtor, were part of the team that first identified CFAK-Y15, in research published in the Journal of Medicinal Chemistry in 2008.


Story Source:

The above story is based on materials provided by Roswell Park Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. V. Golubovskaya, G. Huang, B. Ho, M. Yemma, C. D. Morrison, J. Lee, B. Eliceiri, W. G. Cance. Pharmacological blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Molecular Cancer Therapeutics, 2012; DOI: 10.1158/1535-7163.MCT-12-0701

Cite This Page:

Roswell Park Cancer Institute. "Targeted therapy proves effective against brain tumors in preclinical studies." ScienceDaily. ScienceDaily, 21 December 2012. <www.sciencedaily.com/releases/2012/12/121221123323.htm>.
Roswell Park Cancer Institute. (2012, December 21). Targeted therapy proves effective against brain tumors in preclinical studies. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2012/12/121221123323.htm
Roswell Park Cancer Institute. "Targeted therapy proves effective against brain tumors in preclinical studies." ScienceDaily. www.sciencedaily.com/releases/2012/12/121221123323.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins